$0.6814
0.1732.59%
Last update: Nov 10, 12:57 PM
Estrella Immunopharma Inc
ESLANASDAQ
Estrella Immunopharma fell 80.6% from $2.65 to $0.51, behind the S&P 500's +10.5%. Its worst day was Nov 2 (−33.3%), and its low came Oct 13 at $0.31.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.13 was reported on $0.00 revenue.
+4.8% · S&P 500 −1.7%
Estrella Immunopharma shares rose 26.9%, while the S&P 500 fell 1.2%.
+26.9% · S&P 500 −1.2%
Story events cover the past 12 months · Times ET
EPS of $-0.01 beat the $-0.12 estimate on $0.00 revenue.
−2.7% · S&P 500 −1.4%
Estrella Immunopharma shares rose 29.5%, while the S&P 500 rose 0.5%.
+29.5% · S&P 500 +0.5%
EPS of $-0.05 beat the $-0.12 estimate on $0.00 revenue.
+0.9% · S&P 500 −0.1%
EPS of $-0.05 beat the $-0.09 estimate on $0.00 revenue.
−0.2% · S&P 500 −0.2%
Estrella Immunopharma closed at its lowest level of the year, 88.2% below where the year started.
−4.4% · S&P 500 0.0%
Estrella Immunopharma shares rose 37.5%, while the S&P 500 rose 0.5%.
+37.5% · S&P 500 +0.5%
Estrella Immunopharma shares fell 33.3%, while the S&P 500 fell 0.5%.
−33.3%, the year's worst day · S&P 500 −0.5%
Where it ended: a close of $0.51 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.08).
Nothing in the past 12 months.
All ESLA dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ESLA and SPY from Benzinga historical bars. Not investment advice.
